Jounce Therapeutics News - JNCE

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Jounce Therapeutics Inc JNCE NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 5.84 0.00 0.00 0.00 5.84 19:00:00
more quote information »

Recent News

Date Time Source Heading
2/06/202008:00GLOBEJounce Therapeutics Presents New Vopratelimab Predictive..
1/23/202008:09EDGARStatement of Changes in Beneficial Ownership (4)
1/23/202008:07EDGARInitial Statement of Beneficial Ownership (3)
1/23/202008:06EDGARCurrent Report Filing (8-k)
1/23/202008:00GLOBEJounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E.,..
1/13/202008:02EDGARCurrent Report Filing (8-k)
1/10/202008:54EDGARStatement of Changes in Beneficial Ownership (4)
1/10/202008:54EDGARStatement of Changes in Beneficial Ownership (4)
1/10/202008:54EDGARStatement of Changes in Beneficial Ownership (4)
1/10/202008:54EDGARStatement of Changes in Beneficial Ownership (4)
1/09/202008:00GLOBEJounce Therapeutics to Present at the 38th Annual J.P...
1/08/202016:57EDGARStatement of Changes in Beneficial Ownership (4)
12/26/201917:08EDGARStatement of Changes in Beneficial Ownership (4)
12/19/201915:00GLOBEJounce Therapeutics to Present New Data on a Potential..
12/17/201917:01EDGARCurrent Report Filing (8-k)
12/17/201916:57EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
11/07/201912:08EDGARQuarterly Report (10-q)
11/07/201906:43EDGARCurrent Report Filing (8-k)
11/07/201906:30GLOBEJounce Therapeutics Reports Third Quarter 2019 Financial..
11/05/201908:05GLOBEJounce Therapeutics to Present Safety and Preliminary..
10/31/201908:00GLOBEJounce Therapeutics to Announce Third Quarter 2019 Financial..
10/01/201918:01GLOBEJounce Therapeutics to Present Two Posters from the JTX-4014..
9/17/201908:00GLOBEJounce Therapeutics Names Jacquelyn Fahey Sandell as Chief..
9/04/201908:52EDGARCurrent Report Filing (8-k)
8/28/201908:00GLOBEJounce Therapeutics to Present at Upcoming Investor..
8/07/201911:25EDGARQuarterly Report (10-q)
8/07/201907:17EDGARCurrent Report Filing (8-k)
8/07/201906:30GLOBEJounce Therapeutics Reports Second Quarter 2019 Financial..
7/31/201908:00GLOBEJounce Therapeutics to Announce Second Quarter 2019..
7/23/201916:05EDGARCurrent Report Filing (8-k)
7/23/201916:00GLOBEJounce Therapeutics Announces Update on Strategic..
6/18/201908:00GLOBEJounce Therapeutics Initiates Phase 2 EMERGE Study of..
6/13/201910:33EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:33EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:33EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:32EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:32EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:31EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:31EDGARStatement of Changes in Beneficial Ownership (4)
6/13/201910:27EDGARCurrent Report Filing (8-k)
6/11/201908:00GLOBEJounce Therapeutics to Present at Upcoming Investor..
5/08/201912:46EDGARQuarterly Report (10-q)
5/08/201907:13EDGARCurrent Report Filing (8-k)
5/08/201906:30GLOBEJounce Therapeutics Reports First Quarter 2019 Financial..
5/01/201908:00GLOBEJounce Therapeutics to Announce First Quarter 2019 Financial..
4/23/201908:24EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
4/23/201908:22EDGARProxy Statement (definitive) (def 14a)
4/03/201908:02GLOBEJounce Therapeutics Presents Preclinical Data from JTX-8064..
4/02/201913:02GLOBEJounce Therapeutics Reports Improved PFS and OS Associated..
3/06/201911:20EDGARSecurities Registration: Employee Benefit Plan (s-8)
See more news about this stock »


Your Recent History
NASDAQ
JNCE
Jounce The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.